SCHEMBL3326635

SCHEMBL3326635

O=S(=O)(c1c(Cl)nc2sccn12)n1ccc2cc(C3CNC3)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 8/20 0.54
HTR6 P50406 12/20 0.46
HTR2C P28335 3/20 0.46
ADRA2A P08913 2/20 0.46
HTR7 P34969 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2A6 P11509 1/20 0.44
HTR2B P41595 1/20 0.44
ADRB2 P07550 1/20 0.42
CHRM2 P08172 1/20 0.42
S1PR1 P21453 1/20 0.42
C5AR1 P21730 1/20 0.42
SLC6A2 P23975 1/20 0.42
FPR3 P25089 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42
GPR183 P32249 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3328145 0.72 HTR6 (0.59) METHTR6HTR7CYP3A4HTR2A
SCHEMBL3323099 0.72 HTR6 (0.58) HTR6CYP3A4
SCHEMBL4081092 0.72 HTR6 (0.55) METHTR6HTR2CHTR7CYP3A4
SCHEMBL3331201 0.70 HTR6 (0.51) HTR6CYP3A4
SCHEMBL1537829 0.69 MET (0.65) METHTR6HTR2CADRA2AHTR7
SCHEMBL3327051 0.68 HTR6 (0.45) HTR6HTR2CADRA2AHTR7CYP3A4
SCHEMBL3326984 0.68 HTR6 (0.49) HTR6CYP3A4SLC6A2SLC6A3
SCHEMBL3325085 0.68 HTR6 (0.43) HTR6HTR2CCYP3A4
SCHEMBL3325884 0.68 HTR6 (0.40) HTR6CYP3A4
SCHEMBL3207669 0.68 MET (0.48) METHTR6HTR2CADRA2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 US claimed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US claimed
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 US disclosed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR4, HTR3C MET 1235/4885HTR6 1/4885HTR2C 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.